KBC Group NV Has $178.50 Million Stock Holdings in McKesson Corporation $MCK

KBC Group NV lifted its position in shares of McKesson Corporation (NYSE:MCK) by 51.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 217,605 shares of the company’s stock after purchasing an additional 74,287 shares during the quarter. KBC Group NV’s holdings in McKesson were worth $178,499,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp lifted its holdings in McKesson by 0.9% during the third quarter. State Street Corp now owns 5,750,519 shares of the company’s stock worth $4,447,110,000 after acquiring an additional 51,510 shares in the last quarter. Franklin Resources Inc. increased its holdings in shares of McKesson by 3.5% in the third quarter. Franklin Resources Inc. now owns 2,681,321 shares of the company’s stock worth $2,071,428,000 after acquiring an additional 90,948 shares in the last quarter. Alliancebernstein L.P. raised its position in shares of McKesson by 5.6% during the third quarter. Alliancebernstein L.P. now owns 2,394,699 shares of the company’s stock worth $1,850,001,000 after purchasing an additional 126,684 shares during the period. Northern Trust Corp raised its position in shares of McKesson by 0.4% during the third quarter. Northern Trust Corp now owns 1,532,856 shares of the company’s stock worth $1,184,193,000 after purchasing an additional 6,613 shares during the period. Finally, Boston Partners lifted its holdings in shares of McKesson by 6.7% during the 3rd quarter. Boston Partners now owns 1,330,953 shares of the company’s stock valued at $1,027,569,000 after purchasing an additional 83,357 shares in the last quarter. Institutional investors and hedge funds own 85.07% of the company’s stock.

McKesson Stock Performance

Shares of McKesson stock opened at $862.09 on Thursday. The firm has a market cap of $105.60 billion, a PE ratio of 24.79, a P/E/G ratio of 1.24 and a beta of 0.42. The business’s 50 day simple moving average is $917.65 and its 200 day simple moving average is $853.54. McKesson Corporation has a 52-week low of $637.00 and a 52-week high of $999.00.

McKesson (NYSE:MCK) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share for the quarter, topping the consensus estimate of $9.19 by $0.15. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The company had revenue of $106.16 billion during the quarter, compared to analysts’ expectations of $105.98 billion. During the same period last year, the business earned $8.03 EPS. The business’s quarterly revenue was up 11.4% on a year-over-year basis. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, equities research analysts predict that McKesson Corporation will post 32.77 EPS for the current year.

McKesson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, April 1st. Investors of record on Monday, March 2nd were given a $0.82 dividend. The ex-dividend date of this dividend was Monday, March 2nd. This represents a $3.28 dividend on an annualized basis and a yield of 0.4%. McKesson’s dividend payout ratio (DPR) is 9.43%.

Analyst Upgrades and Downgrades

MCK has been the subject of a number of research reports. Wall Street Zen cut McKesson from a “buy” rating to a “hold” rating in a research note on Saturday, April 11th. Barclays lifted their price target on shares of McKesson from $960.00 to $1,050.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. Bank of America lowered their price objective on shares of McKesson from $1,040.00 to $1,000.00 and set a “buy” rating for the company in a research report on Monday, April 6th. Weiss Ratings lowered shares of McKesson from a “buy (a-)” rating to a “buy (b+)” rating in a report on Thursday, February 5th. Finally, Robert W. Baird set a $968.00 price objective on shares of McKesson in a research report on Wednesday, January 14th. Thirteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $970.93.

Insider Buying and Selling at McKesson

In other news, Director Maria Martinez sold 349 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $939.87, for a total transaction of $328,014.63. Following the completion of the transaction, the director directly owned 301 shares in the company, valued at $282,900.87. This represents a 53.69% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the firm’s stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $955.00, for a total value of $313,240.00. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,592 shares of company stock valued at $3,518,555 over the last quarter. 0.08% of the stock is currently owned by corporate insiders.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.